OBJECTIVES: To report the results of a novel surveillance policy for stage I nonseminomatous germ cell @entity5 (NSGCTs). @entity1 AND METHODS: Between 1978 and 2000, 132 @entity1 (median age 28 years, range 16-52) who were regularly followed were included in a new surveillance policy. All pathology specimens were studied retrospectively by the same pathologist for @entity189 , @entity5 and lymphovascular invasion components. A loose surveillance protocol was designed in which computed tomography (CT) was used only for the first year. RESULTS: The median (range) follow-up was 38 (6-265) months; the relapse rate was 24% and all occurred before 23 months, with 87% diagnosed within the first year. @entity902 -based chemotherapy was given to @entity1 with relapse, and surgery used after chemotherapy in seven. Among all the risk factors, an @entity189 component was the only significant predictor of relapse. The overall survival rate was 99%. CONCLUSION: The presence of @entity189 in the primary pathology is the only risk factor determining the relapse rate of the present surveillance policy for stage I NSGCTs. The overall survival was no different from those reported for retroperitoneal lymph node dissection and primary chemotherapy. Decreasing the frequency of CT in the first year and totally eliminating it after 1 year reduces the cost of surveillance. The possible compliance problems of @entity1 are also minimized, without changing the overall survival. This surveillance protocol for @entity1 with stage I NSGCT has reduced costs and provided a better quality of life for the @entity1 , without jeopardizing the final outcome.

A novel surveillance protocol for stage I nonseminomatous germ cell XXXX .

@entity5 :: ('MESH:D009369', 'Disease') :: ['yolk sac tumour', 'tumours'] @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['Platinum'] @entity189 :: ('MESH:D002277', 'Disease') :: ['embryonal carcinoma']
@entity5 :: (MESH:D009369,Disease) :: ['testicular tumours']
